

bitop and Yuria-Pharm enter a partnership and launch Ectoin® inhalation solution in the Ukraine.

Dortmund, February 17th 2021

We are very happy to announce that our partner Yuria-Pharm, based in Kiev, has launched **Ectoin® Inhalation Solution** under the brand name **ECTOBREATH®** in the Ukrainian market.

The **Ectoin® Inhalation Solution** has been developed by bitop to reduce inflammations of the airways in case of pulmonary diseases such as bronchitis, asthma, or chronic obstructive pulmonary disease (COPD). Containing the 100% natural ingredient Ectoin® the solution has clinically shown superior reduction in bronchitis symptoms compared to traditional saline solutions*.

"The demand we see for our inflammation reducing inhalation solutions has never been as strong as today. People understand, that protecting lungs and airways is a good way to stay healthy. We are very glad to have entered a new market with our new partner Yuria-Pharm in this important indication", states bitop CEO Wolfgang Hansen.

As manufacturer and distributor of a wide range of pharmaceuticals and medical products, Yuria-Pharm has a particularly strong footage in hospitals and healthcare facilities (HLF) in the Ukraine and started the distribution in their home market in early 2021.

About Ectoin® containing OTC-products

For more than ten years, bitop has developed and registered medical devices with Ectoin® and out-licensed these patent-protected products in a full-service model to partners all over the world. The natural protection molecule Ectoin® is made in Germany and provides a 100% natural mode of action. bitop offers products with Ectoin® with clinically proven claims in the categories of Cough&Cold, Allergy, Pulmonary Diseases, Ophthalmology, Dermatology and Supportive Cancer Treatment.

For more information on the product range, please contact <u>info@bitop.de</u> or visit <u>www.bitop.de</u> or contact our sales team directly under <u>bd@bitop.de</u>.



*Tran et al. 2019. Ectoine-Containing Inhalation Solution versus Saline Inhalation Solution in the Treatment of Acute Bronchitis and Acute Respiratory Infections: A Prospective, Controlled, Observational Study. *BioMed Res Intern*, Article ID 7945091.

